Drugs / FAB122
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05866926 | Mar 2023 → Jan 2024 | amyotrophic lateral sclerosis | Ferrer Internacional S.A. | Terminated | No outcome recorded |
| Phase 3 | NCT05178810 | Oct 2021 → Oct 2023 | amyotrophic lateral sclerosis | Ferrer Internacional S.A. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-01-10 | Ferrer Internacional S.A. | Results Ferrer Announces Primary Results of Phase III ADORE Clinical Trial in ALS ferrer.com ↗
Ferrer reports that the Phase III ADORE clinical trial (EudraCT 2020-003376-40 /NCT05178810) with an oral formulation of edaravone (FAB122) in patients with amyotrophic lateral sclerosis (ALS) did not meet the key primary or secondary endpoints. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-01-10 | Ferrer Internacional S.A. | Ferrer Announces Primary Results of Phase III ADORE Clinical Trial in ALS ferrer.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FAB122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05866926 ↗ |
| Known as | Edaravone | “Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis” NCT05178810 ↗ |
| Route | Oral | “as oral formulation” NCT05178810 ↗ |